{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:23:25Z","timestamp":1785885805648,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research Project of Shanghai Municipal Health Commission","award":["20224Y0269"],"award-info":[{"award-number":["20224Y0269"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["YG2023QNA44"],"award-info":[{"award-number":["YG2023QNA44"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019330","name":"Shanghai Clinical Research Center for Mental Health","doi-asserted-by":"publisher","award":["19MC1911100"],"award-info":[{"award-number":["19MC1911100"]}],"id":[{"id":"10.13039\/501100019330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Collaborative Innovation Center for Clinical and Translational Science by Ministry of Education & Shanghai","award":["CCTS-202306, CCTS-202409PT"],"award-info":[{"award-number":["CCTS-202306, CCTS-202409PT"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00869-4","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:13:44Z","timestamp":1740057224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A pharmacovigilance study of olanzapine\/samidorphan based on FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1186","volume":"26","author":[{"given":"Luyao","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"869_CR1","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323. https:\/\/doi.org\/10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"key":"869_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/13651500500409663","volume":"10","author":"T Treuer","year":"2006","unstructured":"Treuer T, Anders M, Bitter I, Dobre G, Pecenak J, Dyachkova Y, Harrison G, O\u2019Mahoney J. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO). Int J Psychiatry Clin Pract. 2006;10:78\u201390. https:\/\/doi.org\/10.1080\/13651500500409663.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"869_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71\u201393. https:\/\/doi.org\/10.1093\/schbul\/sbp116.","journal-title":"Schizophr Bull"},{"key":"869_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/00325481.2019.1701823","volume":"132","author":"AM Meftah","year":"2020","unstructured":"Meftah AM, Deckler E, Citrome L, Kantrowitz JT. New discoveries for an old drug: a review of recent olanzapine research. Postgrad Med. 2020;132:80\u201390. https:\/\/doi.org\/10.1080\/00325481.2019.1701823.","journal-title":"Postgrad Med"},{"key":"869_CR5","doi-asserted-by":"publisher","unstructured":"Wang J, Jiang F, Zhang Y, Cotes RO, Yang Y, Liu Z, Ning X, Liu T, Liu Y, Tang YL, et al. Patterns of antipsychotic prescriptions in patients with schizophrenia in China: A national survey. Asian J Psychiatry. 2021;62. https:\/\/doi.org\/10.1016\/j.ajp.2021.102742.","DOI":"10.1016\/j.ajp.2021.102742"},{"key":"869_CR6","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1096\/fj.12-208041","volume":"26","author":"TA Czyzyk","year":"2012","unstructured":"Czyzyk TA, Romero-Pic\u00f3 A, Pintar J, McKinzie JH, Tsch\u00f6p MH, Statnick MA, Nogueiras R. Mice lacking \u03b4-opioid receptors resist the development of diet-induced obesity. FASEB Journal: Official Publication Federation Am Soc Experimental Biology. 2012;26:3483\u201392. https:\/\/doi.org\/10.1096\/fj.12-208041.","journal-title":"FASEB Journal: Official Publication Federation Am Soc Experimental Biology"},{"key":"869_CR7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1096\/fj.09-143610","volume":"24","author":"TA Czyzyk","year":"2010","unstructured":"Czyzyk TA, Nogueiras R, Lockwood JF, McKinzie JH, Coskun T, Pintar JE, Hammond C, Tsch\u00f6p MH, Statnick MA. Kappa-opioid receptors control the metabolic response to a high-energy diet in mice. FASEB Journal: Official Publication Federation Am Soc Experimental Biology. 2010;24:1151\u20139. https:\/\/doi.org\/10.1096\/fj.09-143610.","journal-title":"FASEB Journal: Official Publication Federation Am Soc Experimental Biology"},{"key":"869_CR8","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.2337\/diabetes.54.12.3510","volume":"54","author":"A Tabarin","year":"2005","unstructured":"Tabarin A, Diz-Chaves Y, Carmona Mdel C, Catargi B, Zorrilla EP, Roberts AJ, Coscina DV, Rousset S, Redonnet A, Parker GC, et al. Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a thrifty gene. Diabetes. 2005;54:3510\u20136. https:\/\/doi.org\/10.2337\/diabetes.54.12.3510.","journal-title":"Diabetes"},{"key":"869_CR9","doi-asserted-by":"publisher","first-page":"104115","DOI":"10.1016\/j.amsu.2022.104115","volume":"79","author":"ST Rehan","year":"2022","unstructured":"Rehan ST, Siddiqui AH, Khan Z, Imran L, Syed AA, Tahir MJ, Jassani Z, Singh M, Asghar MS, Ahmed A. Samidorphan\/olanzapine combination therapy for schizophrenia: efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Annals Med Surg (2012). 2022;79:104115. https:\/\/doi.org\/10.1016\/j.amsu.2022.104115.","journal-title":"Annals Med Surg (2012)"},{"key":"869_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jad.2022.01.004","volume":"301","author":"MY Jawad","year":"2022","unstructured":"Jawad MY, Alnefeesi Y, Lui LMW, Ceban F, Chen-Li DCJ, Teopiz K, Jaberi S, Gillissie ES, Vincenzo JDD, Rosenblat JD, et al. Olanzapine and samidorphan combination treatment: a systematic review. J Affect Disord. 2022;301:99\u2013106. https:\/\/doi.org\/10.1016\/j.jad.2022.01.004.","journal-title":"J Affect Disord"},{"key":"869_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","volume":"176","author":"WF Martin","year":"2019","unstructured":"Martin WF, Correll CU, Weiden PJ, Jiang Y, Pathak S, DiPetrillo L, Silverman BL, Ehrich EW. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: A randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176:457\u201367. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18030280.","journal-title":"Am J Psychiatry"},{"key":"869_CR12","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s40265-021-01568-0","volume":"81","author":"J Paik","year":"2021","unstructured":"Paik J. Olanzapine\/Samidorphan: first approval. Drugs. 2021;81:1431\u20136. https:\/\/doi.org\/10.1007\/s40265-021-01568-0.","journal-title":"Drugs"},{"key":"869_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1177\/10600280211070330","volume":"56","author":"C Monahan","year":"2022","unstructured":"Monahan C, McCoy L, Powell J, Gums JG. Olanzapine\/Samidorphan: new drug approved for treating bipolar I disorder and Schizophrenia. Annals Pharmacotherapy. 2022;56:1049\u201357. https:\/\/doi.org\/10.1177\/10600280211070330.","journal-title":"Annals Pharmacotherapy"},{"key":"869_CR14","doi-asserted-by":"publisher","unstructured":"Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, Liu Z, Cheng Q, Zhang J, Luo P. Psychiatric disorders associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. eClinicalMedicine. 2023;59. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101967.","DOI":"10.1016\/j.eclinm.2023.101967"},{"key":"869_CR15","doi-asserted-by":"publisher","unstructured":"He L, Yu Y, Wei Y, Huang J, Shen Y, Li H. Characteristics and spectrum of cardiotoxicity induced by various antipsychotics: A real-world study from 2015 to 2020 based on FAERS. 2022;12. https:\/\/doi.org\/10.3389\/fphar.2021.815151","DOI":"10.3389\/fphar.2021.815151"},{"key":"869_CR16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2011.1360","volume":"306","author":"AR Maher","year":"2011","unstructured":"Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359\u201369. https:\/\/doi.org\/10.1001\/jama.2011.1360.","journal-title":"JAMA"},{"key":"869_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","volume":"61","author":"N Bhana","year":"2001","unstructured":"Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61:111\u201361. https:\/\/doi.org\/10.2165\/00003495-200161010-00011.","journal-title":"Drugs"},{"key":"869_CR18","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.bmcl.2009.02.078","volume":"19","author":"MP Wentland","year":"2009","unstructured":"Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, Ganorkar R, VanAlstine MA, Guo C, Cohen DJ, et al. Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009;19:2289\u201394. https:\/\/doi.org\/10.1016\/j.bmcl.2009.02.078.","journal-title":"Bioorg Med Chem Lett"},{"key":"869_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1124\/jpet.118.249839","volume":"367","author":"JM Bidlack","year":"2018","unstructured":"Bidlack JM, Knapp BI, Deaver DR, Plotnikava M, Arnelle D, Wonsey AM, Fern Toh M, Pin SS, Namchuk MN. In Vitro Pharmacological characterization of Buprenorphine, Samidorphan, and combinations being developed as an adjunctive treatment of major depressive disorder. J Pharmacol Exp Ther. 2018;367:267\u201381. https:\/\/doi.org\/10.1124\/jpet.118.249839.","journal-title":"J Pharmacol Exp Ther"},{"key":"869_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00213-024-06554-4","volume":"241","author":"W Storck","year":"2024","unstructured":"Storck W, de Laportali\u00e8re TT, Yrondi A, Javelot H, Berna F, Montastruc F. Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (vigibase) between 2000 and 2022. Psychopharmacology. 2024;241:1205\u201312. https:\/\/doi.org\/10.1007\/s00213-024-06554-4.","journal-title":"Psychopharmacology"},{"key":"869_CR21","doi-asserted-by":"publisher","unstructured":"Yee B, Looi JCL, Agaciak M, Allison S, Chan SKW, Bastiampillai T. Non-Psychosis Symptoms of Clozapine Withdrawal: a Systematic Review. East Asian archives of psychiatry: official journal of the Hong Kong College of Psychiatrists\u2009=\u2009Dong Ya jing shen ke xue zhi: Xianggang jing shen ke yi xue yuan qi kan. 2023;3:44\u201364. https:\/\/doi.org\/10.12809\/eaap2261","DOI":"10.12809\/eaap2261"},{"key":"869_CR22","unstructured":"U.S. Food and Drug Administration. LYBALVI (olanzapine and samidorphan) [package insert]. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/213378s009lbl.pdf. Accessed 02 August 2025."},{"key":"869_CR23","doi-asserted-by":"publisher","first-page":"230e231","DOI":"10.1016\/j.ajem.2024.03.027","volume":"79","author":"A Chambers","year":"2024","unstructured":"Chambers A, Patton J, Wills BK. Precipitated opioid withdrawal in a patient started on olanzapine\/samidorphan. Am J Emerg Med. 2024;79:230e231. 230.e232.","journal-title":"Am J Emerg Med"},{"key":"869_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaclp.2022.09.004","volume":"64","author":"P Eigenberger","year":"2023","unstructured":"Eigenberger P, Desan P, Caro MA. A case of Opioid Withdrawal precipitated by Samidorphan \/ Olanzapine in a patient taking buprenorphine \/ naloxone. J Acad Consultation-Liaison Psychiatry. 2023;64:94\u20135. https:\/\/doi.org\/10.1016\/j.jaclp.2022.09.004.","journal-title":"J Acad Consultation-Liaison Psychiatry"},{"key":"869_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/15563650.2022.2049286","volume":"60","author":"NM Warstadt","year":"2022","unstructured":"Warstadt NM, Schmitz ZP, Soghoian SE. Olanzapine\/samidorphan precipitated opioid withdrawal in a patient taking transdermal fentanyl. Clin Toxicol (Phila). 2022;60:891\u20132. https:\/\/doi.org\/10.1080\/15563650.2022.2049286.","journal-title":"Clin Toxicol (Phila)"},{"key":"869_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/jcp.0000000000001501","volume":"42","author":"L He","year":"2022","unstructured":"He L, Yu Y, Zhang L, He S, Yu W, Li L, Huang J, Li H. A real-world study of risk factors for QTc prolongation in Schizophrenia patients receiving atypical antipsychotics. J Clin Psychopharmacol. 2022;42:71\u20134. https:\/\/doi.org\/10.1097\/jcp.0000000000001501.","journal-title":"J Clin Psychopharmacol"},{"key":"869_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40264-013-0032-z","volume":"36","author":"E Poluzzi","year":"2013","unstructured":"Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F. Antipsychotics and torsadogenic risk: signals emerging from the US FDA adverse event reporting System database. Drug Saf. 2013;36:467\u201379. https:\/\/doi.org\/10.1007\/s40264-013-0032-z.","journal-title":"Drug Saf"},{"key":"869_CR28","doi-asserted-by":"publisher","first-page":"109881","DOI":"10.1016\/j.pnpbp.2020.109881","volume":"100","author":"L Sun","year":"2020","unstructured":"Sun L, Yagoda S, Xue H, Brown R, Nangia N, McDonnell D, Rege B, von Moltke L, Darpo B. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: results from a phase 1 QT\/QTc study. Prog Neuro-psychopharmacol Biol Psychiatry. 2020;100:109881. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109881.","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"key":"869_CR29","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C, Ponti F. Data mining techniques in pharmacovigilance: Analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). 2012.","DOI":"10.5772\/50095"},{"key":"869_CR30","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389. https:\/\/doi.org\/10.1016\/s1470-2045(18)30608-9.","journal-title":"Lancet Oncol"},{"key":"869_CR31","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, H\u00f6cker J. OpenVigil FDA - Inspection of U.S. American adverse drug events Pharmacovigilance Data and Novel Clinical Applications. PLoS ONE. 2016;11:e0157753. https:\/\/doi.org\/10.1371\/journal.pone.0157753.","journal-title":"PLoS ONE"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00869-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00869-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00869-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:13:52Z","timestamp":1740057232000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00869-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["869"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00869-4","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}